Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)

News
2026
2025
Archive
Search news articles

September 30, 2026

Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)
September 9, 2026

Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
August 17, 2026

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 7, 2026

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
August 7, 2026

CAMP4 advances rare disease treatment for SYNGAP1 into human trials
July 28, 2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 23, 2026

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma
July 23, 2026

Nouscom Selected for Oral Presentation on NOUS-209 Re-Treatment and Long-Term Follow-up in Lynch Syndrome Carriers at ESMO Congress 2026
June 10, 2026

Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
May 19, 2026

NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress

1
2
3
…
131
Next Page »